NDA 022256 · Abbvie
Savella
Milnacipran Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Sep 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jan 14, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
73
24 Phase 3, 1 recruiting
FAERS reports
6,009
2,554 serious, 156 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Milnacipran hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of depression and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of such drugs in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are...
What it is approved for
From the label in effect Mar 19, 2026.
Milnacipran hydrochloride is indicated for the management of fibromyalgia. Milnacipran hydrochloride is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . • Milnacipran hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia ( 1 ). • Milnacipran hydrochloride is not approved for use in pediatric patients ( 1 ).
Mechanism: The exact mechanism of the central pain inhibitory action of milnacipran and its ability to improve the symptoms of fibromyalgia in humans are unknown. Preclinical studies have shown that milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other neurotransmitters. Milnacipran has no significant affinity for serotonergic (5-HT1-7), α- and β-adrenergic, muscarinic (M1-5), histamine (H1-4), dopamine...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 14, 2009 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLetter
4 products under this application
- SAVELLA · MILNACIPRAN HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
- SAVELLA · MILNACIPRAN HYDROCHLORIDE 25MG · TABLET, ORAL · Prescription · TE AB
- SAVELLA · MILNACIPRAN HYDROCHLORIDE 50MG · TABLET, ORAL · Prescription · TE AB
- SAVELLA · MILNACIPRAN HYDROCHLORIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Milnacipran" as an intervention, any sponsor and status, largest first.
- A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia SyndromePivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT00436033 · 1,429 participants · Start Feb 2006 · Primary completion Sep 2007
Drug: milnacipran; Placebo · For: Fibromyalgia Syndrome
Sites: Pardubice, Czechia; Frederiksberg, Denmark; Kuopio, Finland · 13 sites in all
- Study of Milnacipran for the Treatment of FibromyalgiaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00098124 · 1,200 participants · Start Nov 2004
Drug: milnacipran hydrochloride · For: Fibromyalgia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 80 sites in all
- Study of Milnacipran for the Treatment of FibromyalgiaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00314249 · 1,025 participants · Start Apr 2006 · Primary completion Jun 2008
Drug: Placebo; Milnacipran 100mg · For: Fibromyalgia
Sites: Tuscaloosa, Alabama; Fresno, California; Pismo Beach, California · 24 sites in all
- Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic PhenotypeStatus unknown
Samsung Medical CenterAcademic, hospital or other
NCT01352559 · 1,000 participants (planned) · Start Nov 2001 · Primary completion Mar 2007
Drug: responders; non-responders · For: Depression
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT01228357 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Depressive Symptoms
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT00817375 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Adverse Reaction to Drug
Sites: Kangnam, South Korea
- Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01085812 · 734 participants · Start Mar 2010 · Primary completion Oct 2011
Drug: Levomilnacipran ER; Placebo · For: Depression; Major Depressive Disorder
Sites: Beverly Hills, California; Encino, California; Garden Grove, California · 35 sites in all
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00969709 · 724 participants · Start Sep 2009 · Primary completion May 2011
Drug: Levomilnacipran ER; Levomilnacipran ER and 2 more · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Scottsdale, Arizona; Beverly Hills, California · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea699
- pain522
- headache489
- drug ineffective480
- vomiting363
- fatigue347
- dizziness343
- insomnia329
- depression301
- hyperhidrosis288
- off label use276
- anxiety268
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 493 |
| 2010 | 789 |
| 2011 | 586 |
| 2012 | 389 |
| 2013 | 342 |
| 2014 | 304 |
| 2015 | 414 |
| 2016 | 612 |
| 2017 | 375 |
| 2018 | 347 |
| 2019 | 248 |
| 2020 | 251 |
| 2021 | 160 |
| 2022 | 176 |
| 2023 | 139 |
| 2024 | 141 |
| 2025 | 132 |
| 2026 | 87 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Savella (Milnacipran HCl)
2024 spending
$59.3M
Beneficiaries
16,606
82,321 claims
Per beneficiary
$3,572
$7.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $59,799,645 |
| 2021 | $59,927,908 |
| 2022 | $60,127,012 |
| 2023 | $61,126,083 |
| 2024 | $59,322,983 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Moore A, Bidonde J, Fisher E, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
Fava GA, Benasi G, Lucente M, et al. · Psychother Psychosom 2018 · Systematic Review
- Antidepressants for pain management in adults with chronic pain: a network meta-analysis.
Birkinshaw H, Friedrich CM, Cole P, et al. · Cochrane Database Syst Rev 2023 · Research Support, Non-U.S. Gov't, Review
- Antidepressants for pain management in adults with chronic pain: a network meta-analysis.
Birkinshaw H, Friedrich C, Cole P, et al. · Health Technol Assess 2024 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2009 · Comparative Study, Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.